Material Weakness (new) — Company disclosed material weaknesses in financial close process (inadequate segregation of duties, insufficient documentation) and IT system controls (user access, change management) during 2024-2025 audits.

NASDAQ: COAG Hemab Therapeutics Holdings, Inc. 10-Q

Hemab discloses material control weaknesses in debut 10-Q; $317M IPO extends runway to 2029

Filed May 21, 2026 · Period ending March 31, 2026 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade COAG commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · May 25, 2026 12:05 AM